Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Benign autoimmunity to combat malignancy.

× No keyword cloud information.

21 in total

1. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors: E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205

2. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.

Authors: J Y Zhang; W Zhu; H Imai; K Kiyosawa; E K Chan; E M Tan
Journal: Clin Exp Immunol Date: 2001-07 Impact factor: 4.330

3. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.

Authors: L Gao; I Bellantuono; A Elsässer; S B Marley; M Y Gordon; J M Goldman; H J Stauss
Journal: Blood Date: 2000-04-01 Impact factor: 22.113

4. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.

Authors: C Yee; M J Gilbert; S R Riddell; V G Brichard; A Fefer; J A Thompson; T Boon; P D Greenberg
Journal: J Immunol Date: 1996-11-01 Impact factor: 5.422

5. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

Authors: G Zeng; X Wang; P F Robbins; S A Rosenberg; R F Wang
Journal: Proc Natl Acad Sci U S A Date: 2001-03-20 Impact factor: 11.205

6. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

Authors: Y T Chen; M J Scanlan; U Sahin; O Türeci; A O Gure; S Tsang; B Williamson; E Stockert; M Pfreundschuh; L J Old
Journal: Proc Natl Acad Sci U S A Date: 1997-03-04 Impact factor: 11.205

7. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors: Z Qin; T Blankenstein
Journal: Immunity Date: 2000-06 Impact factor: 31.745

8. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors: D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal: Proc Natl Acad Sci U S A Date: 1999-07-20 Impact factor: 11.205

9. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.

Authors: E Sadovnikova; H J Stauss
Journal: Proc Natl Acad Sci U S A Date: 1996-11-12 Impact factor: 11.205

10. Targeting p53 as a general tumor antigen.

Authors: M Theobald; J Biggs; D Dittmer; A J Levine; L A Sherman
Journal: Proc Natl Acad Sci U S A Date: 1995-12-19 Impact factor: 11.205

1 in total

1. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.

Authors: Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal: Biologics Date: 2007-03

1 in total